Merus' Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer Seite 1
23.10.2023 - - 37% ORR and 14.9 months median DOR in 78 evaluable NRG1+ NSCLC patients - 42% ORR and 9.1 months median DOR in 33 evaluable NRG1+ PDAC patients - Sufficient clinical data expected in 1H24 to support potential BLA submissions UTRECHT, The ... Seite 1
United Kingdom Alison Schram Andrew Joe European Society For Medical Oncology Early Access Program Memorial Sloan Kettering Cancer Center
Source: wallstreet-online.de